查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1702634

全球心臟生物植入設備市場、市場規模和佔有率分析－成長趨勢和預測（2025-2033）

Global Cardiac Bio Implant Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球心臟生物植入設備市場規模預計將從 2024 年的 397.6 億美元成長到 2033 年的 741 億美元，2025 年至 2033 年的複合年增長率為 7.16%。由於人口老化、患者意識增強、對微創治療方案的需求不斷增長、心血管疾病患病率上升以及植入技術的進步等因素，市場正在擴大。

推動心臟生物植入設備市場成長的因素

微創手術

由於人口老化、不良的生活習慣和遺傳因素，心血管疾病變得越來越普遍，這推動了心臟生物植入設備市場的成長。植入材料和設計技術的進步已經改善了患者的治療效果、提高了設備的耐用性和效率。良好的醫療保健基礎設施、不斷增長的患者知識以及微創手術的廣泛採用進一步推動了需求。強有力的報銷和監管框架以及全球不斷上漲的醫療保健成本正在推動心臟生物植入物市場的成長。

心血管疾病盛行率不斷上升

推動心臟生物植入物市場擴張的關鍵因素是心血管疾病盛行率的上升。隨著冠狀動脈疾病等心臟病變得越來越普遍，對心臟瓣膜、起搏器和支架的需求也不斷增長。大約有 2,010 萬名 20 歲以上的美國人患有冠心病，根據美國疾病管制與預防中心的數據，每 40 秒就會發生一次心臟病發作，每年有 805,000 人患有心臟病。人口老化和心臟病盛行率上升可能會增加對生物植入物的需求。隨著慢性心血管疾病變得越來越普遍，用於治療慢性心血管疾病的複雜生物植入物的需求只會增加，從而推動市場擴張。為了解決日益加重的健康負擔，必須轉向使用更持久、更有效的植入物。

技術進步

心臟生物植入物市場的主要驅動力之一是技術進步。材料、設計和製造技術的進步正在生產出更堅固、更有效和生物相容性更好的植入物。近年來，心臟瓣膜、起搏器和支架等生物醫學植入物變得更加精確、更小，並且針對每個患者進行定制，從而改善了治療效果並降低了風險。 3D 列印、智慧技術和微創手術技術的發展進一步促進了這些設備的使用。這些發展透過改善治療效果和擴大適合心臟生物植入物的患者群體來推動市場擴張。

心臟生物植入設備市場的課題

成本高

高價位是心臟生物植入物市場的一個主要障礙。生物植入設備成本高昂，這是因為其製造過程中採用了先進的技術、材料和製造技術，並且需要專門的手術技術。這可能會限制患者的就醫機會，尤其是在低收入地區和醫療保健系統欠發達的國家。此外，過高的成本可能會給保險公司和醫療保健提供者帶來負擔，並阻礙救生心臟植入物在某些市場的廣泛使用。

監理障礙

心臟生物植入設備領域面臨的最大障礙之一是監管障礙。新技術的監管程序可能漫長而具有課題性，從而延遲市場推出並減緩創新和獲得尖端治療的機會。雖然有必要，但監管機構嚴格的安全性和有效性標準增加了開發新產品所需的時間和費用。小型製造商和新技術可能會特別受到這些問題的影響，這可能會減少競爭並延遲向有需要的患者及時提供有益的心臟生物植入物。

本報告研究了全球心臟生物植入設備市場，並提供了成長動力和課題、每個細分市場的分析以及關鍵參與者。

目錄

第1章簡介

第2章 研究方法

第 3 章執行摘要

第4章 市場動態

  • 成長動力
  • 課題

第5章 全球心臟生物植入設備市場

第6章市佔率分析

  • 依類型
  • 依用途
  • 由最終用戶
  • 依國家/地區

第 7 章 類型

  • 心律調節器
  • ICD（植入式心臟復律去顫器）
  • CRT（心臟再同步治療）

第 8 章用途

  • 心律不整
  • 心肌缺血
  • 急性心肌梗塞
  • 心臟衰竭

第 9 章 最終使用者

  • 醫院
  • 門診手術中心
  • 心導管室
  • 其他

第10章 國

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 比利時
    • 荷蘭
    • 土耳其
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 泰國
    • 馬來西亞
    • 印尼
    • 澳大利亞
    • 紐西蘭
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
  • 其他地區

第 11 章 波特五力分析

第 12 章 SWOT 分析

第13章主要公司分析

  • F. Hoffman-La Roche
  • Eurofins Scientific
  • Illumina, Inc.
  • Natera Inc.
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Quest Diagnostics
  • Agilent Technologies
簡介目錄

Global Cardiac Bio Implant Devices Market Trends & Summary

Cardiac Bio Implant Devices Market is expected to reach US$ 74.10 billion in 2033 from US$ 39.76 billion in 2024, with a CAGR of 7.16% from 2025 to 2033. The market for cardiac bioimplants is expanding due to factors such as aging populations, improved patient awareness, growing demand for minimally invasive treatment choices, rising prevalence of cardiovascular disease, and developments in implant technology.

Cardiac Bio Implant Market Global Report by Type (Pacemaker, ICDs (Implantable Cardioverter Defibrillator), CRT (Cardiac Resynchronization Therapy)), Application (Arrhythmias, Myocardial Ischemia, Acute Myocardial Infarction, Heart Failure), End-User (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Laboratories, Others), Countries and Company Analysis 2025-2033.

Cardiac Bio Implant Devices Industry Overview

Patients with cardiovascular disorders can benefit from cardiac bioimplants, which are medical devices that replace or support damaged heart components. These implants consist of artificial cardiac pumps, pacemakers, stents, and heart valves. The danger of rejection is reduced by the smooth integration of cardiac bioimplants, which are made of biocompatible materials. Usually, they are used to treat heart failure, arrhythmias, and aortic stenosis. Technological developments have made cardiac bioimplants more effective, long-lasting, and minimally invasive, improving patient outcomes, shortening recovery periods, and providing a better way to treat complicated cardiac disorders.

Due to aging populations, poor lifestyles, and genetic factors, cardiovascular problems are becoming more common, which is driving growth in the cardiac bioimplant devices market. Patient outcomes, device durability, and efficiency have all improved as a result of technological developments in implant materials and designs. Better healthcare infrastructure, increased patient knowledge, and the growing use of minimally invasive procedures are further driving demand. Strong reimbursement and regulatory frameworks, as well as rising healthcare costs worldwide, are all driving the cardiac bioimplant devices market's growth.

Growth Drivers for the Cardiac Bio Implant Devices Market

Minimally Invasive Procedures

Due to aging populations, poor lifestyles, and genetic factors, cardiovascular problems are becoming more common, which is driving growth in the cardiac bioimplant devices market. Patient outcomes, device durability, and efficiency have all improved as a result of technological developments in implant materials and designs. Better healthcare infrastructure, increased patient knowledge, and the growing use of minimally invasive procedures are further driving demand. Strong reimbursement and regulatory frameworks, as well as rising healthcare costs worldwide, are all driving the cardiac bioimplant devices market's growth.

Rising Cardiovascular Disease Prevalence

An important factor propelling the cardiac bioimplant devices market's expansion is the rising incidence of cardiovascular illness. The need for heart valves, pacemakers, and stents is increasing as cardiac diseases, such as coronary artery disease, become increasingly common. About 20.1 million persons in the United States who are 20 years of age or older suffer from coronary heart disease, with one heart attack every 40 seconds, or 805,000 each year, according to the Centers for Disease Control and Prevention. The need for bioimplants will increase as a result of the aging population and the rising prevalence of cardiac disease. The need for sophisticated bioimplants to treat chronic cardiovascular illnesses will only increase as these ailments become more prevalent, propelling market expansion. To address this increasing health burden, a move toward implants that are more permanent and effective will be essential.

Technological Advancements

One of the main factors propelling the market for cardiac bioimplants devices is technological advances. More robust, effective, and biocompatible implants have been created as a result of advancements in materials, design, and manufacturing techniques. These days, bioimplants-like cardiac valves, pacemakers, and stents-are more accurate, smaller, and customized for each patient, which enhances results and lowers risks. The use of these devices has been further boosted by developments in 3D printing, smart technology, and minimally invasive surgical methods. These developments are driving market expansion by improving treatment efficacy and broadening the patient base suitable for cardiac bioimplants.

Challenges in the Cardiac Bio Implant Devices Market

High costs

The market for cardiac bioimplants devices is severely hampered by high prices. The high cost of bioimplant devices is a result of the sophisticated technology, materials, and manufacturing techniques used in their creation as well as the specific surgical techniques needed. Patients' access may be restricted as a result, especially in low-income areas or nations with less developed healthcare systems. Furthermore, exorbitant expenses may put a strain on insurers and healthcare providers, preventing the broad use of life-saving cardiac bioimplants in some markets.

Regulatory Hurdles

One of the biggest obstacles facing the cardiac bioimplant devices sector is regulatory barriers. Innovation and access to cutting-edge therapies may be slowed by the drawn-out and difficult regulatory procedures for new technologies, which can postpone market introduction. Although necessary, regulatory agencies' strict safety and efficacy standards lengthen the time and expense needed to develop new products. Smaller manufacturers or emerging technologies may be especially impacted by these issues, which could reduce competition and delay the timely delivery of beneficial cardiac bioimplants to patients in need.

Cardiac Bio Implant Devices Market Overview by Regions

The market for cardiac bioimplant devices is expanding significantly on a regional basis. Because of its strong research, large prevalence of cardiovascular illnesses, and sophisticated healthcare infrastructures, North America leads the world. Europe is next, where aging populations and new technology are driving up demand. The Asia Pacific region is expanding quickly due to improved medical infrastructure, increased disease rates, and easier access to healthcare. As healthcare investments rise in Latin America and the Middle East, these regions are also growing.

United States Cardiac Bio Implant Devices Market

Due to the high frequency of cardiovascular disorders, such as heart failure and coronary heart disease, the US cardiac bioimplant market is a major global leader. Technological developments in bioimplant devices, such as heart valves, pacemakers, and stents, as well as a strong healthcare system, help the market. Impulse Dynamics approved and introduced the Optimizer Smart Mini Implantable Pulse Generator (IPG) in the United States in April 2022. By treating moderate to severe heart failure, this Class III medical device gives patients even more therapy alternatives.

The demand for cardiac bioimplants is rising due to a number of factors, including an aging population, an increase in illness rates, and growing patient awareness. Furthermore, the U.S. market is growing and innovating due to advantageous reimbursement rules, better medical infrastructure, and continuous research.

Germany Cardiac Bio Implant Devices Market

Due to a strong healthcare system and a high prevalence of cardiovascular illnesses, Germany has one of the biggest cardiac bioimplant markets in Europe. The market for pacemakers, stents, and cardiac valves is growing as a result of an aging population and rising demand for cutting-edge therapies. The adoption of novel bioimplant technologies is facilitated by Germany's emphasis on medical innovation and research as well as its advantageous reimbursement regulations. Continuous improvements in implant materials and design support expansion and enhance patient outcomes nationwide.

India Cardiac Bio Implant Devices Market

The market for cardiac bioimplants is expanding quickly in India because to the rising incidence of cardiovascular diseases (CVDs), which rank among the nation's top causes of mortality. The World Health Organization reports that more than 27% of deaths in India are caused by CVDs. The adoption of cutting-edge medical technologies, increased awareness of cardiac disease, and better healthcare infrastructure all help the industry. Because of government healthcare programs and cost reductions, bioimplants such as heart valves, pacemakers, and stents are becoming more widely available. In the upcoming years, there will likely be a significant increase in demand for cardiac bioimplants due to the growing middle class and the growing medical tourism industry.

Saudi Arabia Cardiac Bio Implant Devices Market

The market for cardiac bioimplants in Saudi Arabia is expanding quickly due to the country's high rate of cardiovascular disorders, which are a major cause of death. The need for sophisticated therapies like pacemakers, stents, and cardiac valves is growing as the population ages and the number of lifestyle-related illnesses rises. The market is expanding as a result of government investments in healthcare infrastructure and advancements in medical technology. Additionally, the use of cardiac bioimplants is accelerating throughout Saudi Arabia owing to an emphasis on patient knowledge and healthcare accessibility.

Global Cardiac Bio Implant Device Market Segments

Type

1. Pacemaker

2. ICDs (Implantable Cardioverter Defibrillator)

3. CRT (Cardiac Resynchronization Therapy)

Application

1. Arrhythmias

2. Myocardial Ischemia

3. Acute Myocardial Infarction

4. Heart Failure

End-User

1. Hospitals

2. Ambulatory Surgical Centers

3. Cardiac Catheterization Laboratories

4. Others

Countries

North America

1. United States

2. Canada

Europe

1. France

2. Germany

3. Italy

4. Spain

5. United Kingdom

6. Belgium

7. Netherlands

8. Turkey

Asia Pacific

1. China

2. Japan

3. India

4. South Korea

5. Thailand

6. Malaysia

7. Indonesia

8. Australia

9. New Zealand

Latin America

1. Brazil

2. Mexico

3. Argentina

Middle East & Africa

1. Saudi Arabia

2. UAE

3. South Africa

Rest of the World

All the Key players have been covered from 5 Viewpoints:

1. Overview

2. Key Persons

3. Product Portfolio

4. Recent Development & Strategies

5. Revenue Analysis

Key Players Analysis

1. F. Hoffman-La Roche

2. Eurofins Scientific

3. Illumina, Inc.

4. Natera Inc.

5. Abbott Laboratories

6. Thermo Fisher Scientific

7. Quest Diagnostics

8. Agilent Technologies

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Cardiac Bio Implant Devices Market

6. Market Share Analysis

  • 6.1 By Type
  • 6.2 By Application
  • 6.3 By End User
  • 6.4 By Countries

7. Type

  • 7.1 Pacemaker
  • 7.2 ICDs (Implantable Cardioverter Defibrillator)
  • 7.3 CRT (Cardiac Resynchronization Therapy)

8. Application

  • 8.1 Arrhythmias
  • 8.2 Myocardial Ischemia
  • 8.3 Acute Myocardial Infarction
  • 8.4 Heart Failure

9. End-User

  • 9.1 Hospitals
  • 9.2 Ambulatory Surgical Centers
  • 9.3 Cardiac Catheterization Laboratories
  • 9.4 Others

10. Countries

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Thailand
    • 10.3.6 Malaysia
    • 10.3.7 Indonesia
    • 10.3.8 Australia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 Saudi Arabia
    • 10.5.2 UAE
    • 10.5.3 South Africa
  • 10.6 Rest of the World

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Key Players Analysis

  • 13.1 F. Hoffman-La Roche
    • 13.1.1 Overview
    • 13.1.2 Key Persons
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Development & Strategies
    • 13.1.5 Revenue Analysis
  • 13.2 Eurofins Scientific
    • 13.2.1 Overview
    • 13.2.2 Key Persons
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Development & Strategies
    • 13.2.5 Revenue Analysis
  • 13.3 Illumina, Inc.
    • 13.3.1 Overview
    • 13.3.2 Key Persons
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Development & Strategies
    • 13.3.5 Revenue Analysis
  • 13.4 Natera Inc.
    • 13.4.1 Overview
    • 13.4.2 Key Persons
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Development & Strategies
    • 13.4.5 Revenue Analysis
  • 13.5 Abbott Laboratories
    • 13.5.1 Overview
    • 13.5.2 Key Persons
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Development & Strategies
    • 13.5.5 Revenue Analysis
  • 13.6 Thermo Fisher Scientific
    • 13.6.1 Overview
    • 13.6.2 Key Persons
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Development & Strategies
    • 13.6.5 Revenue Analysis
  • 13.7 Quest Diagnostics
    • 13.7.1 Overview
    • 13.7.2 Key Persons
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Development & Strategies
    • 13.7.5 Revenue Analysis
  • 13.8 Agilent Technologies
    • 13.8.1 Overview
    • 13.8.2 Key Persons
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Development & Strategies
    • 13.8.5 Revenue Analysis